Author

Mireia Torres

Observed institutions: Grifols (Spain), Grifols (United States)

OpenAlex ID: A5112931331

Effects of Albumin Treatment on Systemic and Portal Hemodynamics and Systemic Inflammation in Patients With Decompensated Cirrhosis

2019 · Javier Fernández, Joan Clària, et al. · Gastroenterology · 277

PDF

A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study

2020 · Mercè Boada, Oscar L. López, et al. · Alzheimer s & Dementia · 145

PDF

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial

2016 · Mercè Boada, Fernando Anaya, et al. · Journal of Alzheimer s Disease · 96

PDF

Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress

2019 · Mercè Boada, Oscar López, et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 92

PDF

Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer’s Disease Patients Treated with Plasma Exchange with 5% Human Albumin

2017 · Gemma Cuberas-Borrós, Isabel Roca, et al. · Journal of Alzheimer s Disease · 28

PDF

Effect of plasma exchange with albumin replacement on albumin functionality and organ dysfunction in acute-on-chronic liver failure

2024 · Javier Fernández, Miquel Lozano, et al. · JHEP Reports · 17

PDF

Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double‐blind, placebo‐controlled phase 2 study

2025 · María Pascual‐Lucas, Ana María Lacosta, et al. · Alzheimer s & Dementia · 10

PDF

LBO-003 Efficacy and safety of long-term human albumin therapy in cirrhotic patients with acute decompensation and ascites: topline results of the PRECIOSA trial

2025 · Jacqueline G. O’Leary, Giovanni Perricone, et al. · Journal of Hepatology · 9

LBO-002 Plasma exchange with albumin 5% significantly increases 90-day overall survival in acute-on-chronic liver failure: topline results of the APACHE trial

2026 · Javier Fernández, Nikolaos Pyrsopoulos, et al. · Journal of Hepatology · 6

Efficacy and safety evaluation of Fanhdi®, a plasma‐derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study

2021 · Victor Jimenez‐Yuste, Laura Núñez, et al. · Haemophilia · 5

PDF

P2‐448: Peripheral amyloid‐beta mobilization with the intravenous immunoglobulin Flebogamma DIF® in Alzheimer's disease patients

2011 · Mercè Boada Rovira, Laura Núñez, et al. · Alzheimer s & Dementia · 5

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trial

2023 · Andrea Alemany, Pere Millat-Martinez, et al. · EClinicalMedicine · 4

P-5 Apache Study Design to Evaluate the Efficacy and Safety of Plasma Exchange With Human Serum Albumin 5% on Short-term Survival in Patients With Acute-on-chronic Liver Failure at High Risk of Hospital Mortality.

2024 · Nikolaos Pyrsopoulos, Giovanni Perricone, et al. · Annals of Hepatology · 2

P-3 Plasma Exchange With Albumin Increases Effective Albumin Levels in Patients With Acute-on-chronic Liver Failure

2023 · Raquel Horrillo, Anna Mestre, et al. · Annals of Hepatology · 1

P1‐048: Changes in Cognitive Status of Alzheimer’s Disease Patients Treated with Plasma Exchange and Replacement with Human Albumin Plus Immunoglobulin: Interim Global Results of the Ambar Trial

2016 · Mercè Boada, Oscar L. Lopez, et al. · Alzheimer s & Dementia · 1

P3‐403: Longitudinal neuroimaging analysis in Alzheimer's disease after plasma exchange with 5% Grifols albumin (Albutein®)

2012 · Isabel Roca, Mercè Boada‐Rovira, et al. · Alzheimer s & Dementia · 1

A Randomized, Open-Label, Parallel Group Study of Alpha-1 Antitrypsin Therapy in Hospitalized Patients With COVID-19

2026 · Luis Puente Maestu, Myriam Calle Rubio, et al. · Archivos de Bronconeumología

Long‐term safety and immunogenicity of ABvac40 active immunotherapy in mild cognitive impairment and very mild Alzheimer's disease: Results from AB1601 phase 2 extension study

2026 · María Pascual‐Lucas, Ana María Lacosta, et al. · Alzheimer s & Dementia

FRI-100 Cell-free DNA as a biomarker of liver fibrosis in alcohol-related liver disease

2026 · Paola Zuluaga Blanco, Daniel Fuster, et al. · Journal of Hepatology

Safety and Efficacy of the Use of pdVWF/FVIII-C in Patients with von Willebrand Disease: A Prospective, Observational, Post-Authorization Study

2025 · Olga Benítez Hidalgo, Cristina Marzo Alonso, et al. · Clinical and Applied Thrombosis/Hemostasis

WED-059 Effects of albumin treatment on cell death markers in patients with decompensated cirrhosis and in acute-on-chronic liver failure

2024 · Estefania Alcaraz, Anna Mestre, et al. · Journal of Hepatology

FRI-121 Safetyand tolerability of long-term albumin treatment in patients with decompensated cirrhosis

2024 · Javier Fernández, Laura Núñez, et al. · Journal of Hepatology

Long-term 20% albumin administration normalizes the plasma albumin binding capacity in patients with decompensated cirrhosis

2020 · Raquel Horrillo, Anna Mestre, et al. · Journal of Hepatology

P1‐337: Results of a phase II study of plasma exchange with 5 percent albumin (Albutein®) in Alzheimer's disease patients

2012 · Mercè Boada‐Rovira, Laura Nunez Domenech, et al. · Alzheimer s & Dementia

Works count: 24

Citation count: 699

H-index: 8

I10-index: 7